CRISPR Therapeutics’ (CRSP) “Market Outperform” Rating Reiterated at JMP Securities

JMP Securities reissued their market outperform rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a $86.00 price target on the stock.

A number of other equities research analysts have also recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. Truist Financial increased their target price on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Chardan Capital reduced their price target on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a research report on Thursday. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, CRISPR Therapeutics presently has an average rating of “Hold” and an average price target of $74.50.

CRISPR Therapeutics Trading Up 14.3 %

Shares of CRISPR Therapeutics stock opened at $49.72 on Thursday. The firm has a market capitalization of $4.24 billion, a P/E ratio of -17.57 and a beta of 1.67. CRISPR Therapeutics has a 12 month low of $36.52 and a 12 month high of $91.10. The business’s fifty day simple moving average is $41.89 and its 200 day simple moving average is $46.10.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. Analysts predict that CRISPR Therapeutics will post -5.08 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Samarth Kulkarni sold 15,000 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the transaction, the chief executive officer now directly owns 181,540 shares in the company, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Capital Market Strategies LLC bought a new position in shares of CRISPR Therapeutics during the 4th quarter valued at about $461,000. KBC Group NV lifted its position in CRISPR Therapeutics by 2,047.4% in the 4th quarter. KBC Group NV now owns 60,514 shares of the company’s stock worth $2,382,000 after buying an additional 57,696 shares during the last quarter. Capital Advisors Inc. OK lifted its position in CRISPR Therapeutics by 8.1% in the 3rd quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock worth $14,122,000 after buying an additional 22,583 shares during the last quarter. Geode Capital Management LLC grew its position in CRISPR Therapeutics by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after acquiring an additional 35,196 shares during the last quarter. Finally, State Street Corp grew its position in CRISPR Therapeutics by 25.0% during the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after acquiring an additional 599,304 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.